Guizhou Xinbang Pharmaceutical Co., Ltd. (SHE:002390)
China flag China · Delayed Price · Currency is CNY
2.930
-0.040 (-1.35%)
Nov 13, 2026, 3:04 PM CST

SHE:002390 Cash Flow Statement

Millions CNY. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Net Income
138.38120.29101.38287.23224.37272.87
Depreciation & Amortization
195.79198.08218.1236.71243.55247.33
Other Amortization
20.7418.4616.8919.122628.26
Loss (Gain) From Sale of Assets
3.483.482.29-0.0200.42
Asset Writedown & Restructuring Costs
12.6312.631.110.562.134.04
Loss (Gain) From Sale of Investments
-19.74-19.74-2.93-9.4-37.43-3.92
Provision & Write-off of Bad Debts
24.5824.5849.5764.9240.6126.68
Other Operating Activities
328.57171.72102.8108.47127.69204.77
Change in Accounts Receivable
288.64288.64334.13103.2994.98-609.77
Change in Inventory
147.63147.63-63.6424.42-97.01-92.31
Change in Accounts Payable
-204.41-204.41-116.89-33.65-108.32372.58
Change in Other Net Operating Assets
----80.8416.13
Operating Cash Flow
907.47732.53634.97790.62590.8457.97
Operating Cash Flow Growth
36.11%15.37%-19.69%33.82%29.00%-38.29%

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Capital Expenditures
-45.01-85.42-124.87-135.78-158.78-253.76
Sale of Property, Plant & Equipment
6.226.332.65134.980.550.87
Cash Acquisitions
------296.17
Divestitures
14--36.551.610.68
Investment in Securities
-3.5420.743.13.074.63-242.55
Other Investing Activities
36.9219.834.0811.4433.9746.59
Investing Cash Flow
8.58-38.51-115.0350.26-118.02-744.34

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Short-Term Debt Issued
---1,2111,9852,112
Long-Term Debt Issued
-440895.1---
Total Debt Issued
351440895.11,2111,9852,112
Short-Term Debt Repaid
----1,817-2,019-4,257
Long-Term Debt Repaid
--766.2-900.1---
Total Debt Repaid
-482.1-766.2-900.1-1,817-2,019-4,257
Net Debt Issued (Repaid)
-131.1-326.2-5-606.19-34.1-2,145
Issuance of Common Stock
-----1,505
Repurchase of Common Stock
-15.91-8.95-78.99-141.4--
Common Dividends Paid
-181.31-130.82-192.29-158.23-168.36-230.34
Other Financing Activities
-73.93-121.24-41.63-1.3813.03-39.76
Financing Cash Flow
-402.25-587.21-317.91-907.2-189.42-910.57

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Foreign Exchange Rate Adjustments
00-000-0
Net Cash Flow
513.8106.81202.03-66.32283.35-1,197

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Free Cash Flow
862.46647.11510.1654.84432.02204.21
Free Cash Flow Growth
50.89%26.86%-22.10%51.58%111.56%-66.19%
Free Cash Flow Margin
17.20%11.52%8.46%10.13%6.80%3.16%
Free Cash Flow Per Share
0.460.340.270.340.230.11
Levered Free Cash Flow
876.39696.72597.17569.17314.65-37.54
Unlevered Free Cash Flow
877.8708.25611.88593.98347.0225.08

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Cash Income Tax Paid
234.77243.52222.01236.11227.09258.49
Change in Working Capital
203.04203.04145.7683.02-36.13-322.49